Relief from Royalty (RFR) Method

Valuation Methods — Lesson 2 of 10

The Relief from Royalty method is the most widely applied technique for valuing intangible assets in professional practice. Its logic is elegant: if you own an intangible asset — a brand, a patent, a piece of proprietary technology — you are relieved of the obligation to pay a royalty to license it from someone else. The value of the asset is the present value of those avoided royalty payments.

RFR is favoured by valuers, auditors, and tax authorities because it anchors the valuation to observable market data — royalty rates from licensing agreements between unrelated parties. This market anchor makes RFR more defensible than methods that rely entirely on management projections, and it is the default method for brands, trade names, patents, and technology in most purchase price allocations.

This lesson walks through the method step by step, explains the key judgement areas, and provides a complete worked example.

★ Key Takeaway

The Relief from Royalty method values an intangible asset as the present value of royalty payments the owner avoids by owning rather than licensing the asset. Its strength is its reliance on market-observable royalty rates. Its weakness is sensitivity to the royalty rate selected — a 1% change in the rate can shift the valuation by 20-30%.


The Five-Step Process

Every RFR valuation follows the same fundamental sequence, regardless of the asset being valued.

1. Project the revenue base

Identify the revenue stream attributable to the asset and project it over the asset's useful life. For a brand, this is typically total branded revenue. For a patent, it is the revenue from products covered by the patent claims.

2. Select the royalty rate

Determine the arm's-length royalty rate that a willing licensee would pay to use the asset. This is derived from comparable licensing agreements, industry benchmarks, and the profit split between licensor and licensee.

3. Calculate the royalty savings

Multiply projected revenue by the royalty rate, then deduct the tax effect (since royalty payments would be tax-deductible). The after-tax royalty savings represent the economic benefit of ownership.

4. Discount to present value

Apply an appropriate discount rate to convert future royalty savings into today's value. The discount rate reflects the risk profile of the asset and the revenue stream.

5. Add the Tax Amortisation Benefit

If applicable, add the present value of tax savings from amortising the intangible asset over its useful life. This is the Tax Amortisation Benefit (TAB).


Step 1: Projecting Revenue

The revenue base must be directly attributable to the asset. This is more nuanced than it appears.

For a brand or trade name, the revenue base is typically total revenue generated under that brand. If a company operates multiple brands, only the revenue of the brand being valued is included.

For a patent, the revenue base is the revenue from products or services that are covered by the patent claims. If a product relies on multiple patents, the revenue must be apportioned — which introduces a layer of judgement.

For proprietary technology, the revenue base is the revenue from products or services that incorporate the technology. If the technology is one component of a larger product, a contribution analysis may be needed to isolate the relevant revenue.

The projection period should match the asset's estimated useful life. For a patent with 12 years remaining, the projection runs for 12 years. For a brand with an indefinite useful life, the projection includes an explicit forecast period (typically 5-10 years) plus a terminal value.


Step 2: Selecting the Royalty Rate

The royalty rate is the single most important input in an RFR valuation. A 1% change in the royalty rate applied to a $100 million revenue stream changes the annual royalty savings by $1 million — and the present value of the asset by $5-8 million over a typical useful life.

Sources of Royalty Rate Evidence

Source Reliability Application
Comparable licensing agreements (third-party) Highest Direct evidence of arm's-length rates
Industry royalty rate databases (RoyaltyStat, ktMINE) High Statistical benchmarks by industry and asset type
Profit split analysis Moderate Estimates the share of profit attributable to the intangible
25% rule of thumb Low (deprecated) Historically used; no longer accepted by most standards
⚠ Warning

The "25% rule" — which held that a licensee should pay 25% of operating profits as a royalty — was rejected by the US Tax Court in Uniloc v. Microsoft (2011) and is no longer considered reliable evidence. Do not use it as a primary basis for royalty rate selection. It may serve as a rough sanity check but nothing more.

Typical Royalty Rate Ranges

Royalty Rates by Asset Type

Asset Type Typical Range Key Drivers
Consumer brand (established) 3-8% of revenue Brand strength, market position, category
Pharmaceutical patent 4-10% of net sales Stage of development, market exclusivity period
Software / technology 5-15% of revenue Criticality, substitutability, competitive advantage
Industrial patent 2-6% of revenue Scope of claims, enforceability, remaining life
Trade name (B2B) 1-3% of revenue Customer awareness, switching costs

These ranges are indicative. The specific rate must be supported by comparable evidence relevant to the asset being valued.


Step 3: Calculating Royalty Savings

The royalty savings are calculated as:

After-tax royalty savings = Revenue x Royalty rate x (1 - Tax rate)

The tax adjustment is necessary because royalty payments would be tax-deductible expenses. By owning the asset rather than licensing it, the company avoids the royalty payment but also loses the tax deduction. The after-tax royalty savings reflect the net economic benefit.


Step 4: Selecting the Discount Rate

The discount rate converts future royalty savings into present value. It must reflect the risk of the specific cash flows being discounted — not the risk of the business as a whole.

For intangible assets, the discount rate is typically higher than the company's weighted average cost of capital (WACC) because intangible cash flows are generally riskier than the overall business cash flows. The specific premium depends on the asset type:

Asset Risk Profile Typical Discount Rate Range Examples
Low risk WACC to WACC + 1% Established brand, long-term contracts
Moderate risk WACC + 1% to WACC + 3% Technology with proven market, patent portfolio
High risk WACC + 3% to WACC + 6% Development-stage technology, unproven brand
Very high risk WACC + 6%+ Early-stage IP, pre-revenue assets
✔ Example

A manufacturing company with a WACC of 10% is valuing its core brand. The brand has been established for 25 years, generates stable revenue, and has high customer recognition. The valuer selects a discount rate of 11% — WACC plus a 1% premium reflecting the brand's relative stability. By contrast, a recently filed patent covering unproven technology might warrant a discount rate of 16-18%.


Step 5: Tax Amortisation Benefit

When an intangible asset is acquired (rather than internally generated), the acquirer can typically amortise it for tax purposes over its useful life. This creates a tax shield — a series of tax savings that has its own present value.

The TAB is calculated as:

TAB = Asset value x Tax rate x Present value annuity factor

The TAB is then added to the pre-TAB value to arrive at the final fair value. The TAB typically adds 8-15% to the pre-TAB value, depending on the tax rate and useful life.


Worked Example: Patent Portfolio Valuation

Consider PharmaCo, which holds a portfolio of 5 granted patents covering a cardiovascular drug compound. The patents have a weighted average remaining life of 10 years. The drug generates annual revenue of $200 million.

RFR Calculation — PharmaCo Patent Portfolio

Year Revenue ($M) Royalty Rate Gross Savings ($M) Tax (25%) After-Tax Savings ($M) PV Factor (12%) Present Value ($M)
1 200.0 7.0% 14.0 3.5 10.5 0.893 9.4
2 210.0 7.0% 14.7 3.7 11.0 0.797 8.8
3 218.0 7.0% 15.3 3.8 11.5 0.712 8.2
4 222.0 7.0% 15.5 3.9 11.7 0.636 7.4
5 225.0 7.0% 15.8 3.9 11.8 0.567 6.7
6 220.0 7.0% 15.4 3.9 11.6 0.507 5.9
7 210.0 7.0% 14.7 3.7 11.0 0.452 5.0
8 195.0 7.0% 13.7 3.4 10.2 0.404 4.1
9 175.0 7.0% 12.3 3.1 9.2 0.361 3.3
10 150.0 7.0% 10.5 2.6 7.9 0.322 2.5
Total 61.3

Key assumptions:

  • Revenue growth of 5% in years 1-4, then declining as generics approach
  • Royalty rate of 7% based on comparable pharmaceutical licensing agreements
  • Tax rate of 25%
  • Discount rate of 12% (WACC of 9% + 3% intangible asset risk premium)

Pre-TAB value: $61.3 million

Adding the Tax Amortisation Benefit (approximately 11% uplift at 25% tax rate, 10-year amortisation life, 12% discount rate):

Fair value including TAB: $68.0 million

Sensitivity to the Royalty Rate

If the royalty rate were 6% instead of 7%, the pre-TAB value would fall to approximately $52.5 million — a 14% reduction. At 8%, it would rise to approximately $70.1 million — a 14% increase. This symmetrical sensitivity underscores why royalty rate selection is the critical judgement in any RFR valuation, and why it must be supported by robust comparable evidence. We cover sensitivity testing in detail in Lesson 7.


Common Pitfalls

Three errors recur in RFR valuations conducted by non-specialists.

Using gross rather than after-tax savings. Royalty payments are tax-deductible. Failing to apply the tax adjustment overstates the value by the tax rate — typically 20-25%.

Applying an enterprise discount rate. The discount rate should reflect the risk of the intangible asset's cash flows, not the overall business. Using WACC without an intangible asset risk premium understates risk and overstates value.

Ignoring the revenue attribution. If a patent covers one product line that generates 40% of total revenue, the RFR should be applied to that 40%, not the entire revenue base.


What Comes Next

In Lesson 3: Multi-Period Excess Earnings, we examine the MPEEM — the method of choice when the asset being valued is the primary driver of the business's cash flows, particularly customer relationships in a purchase price allocation.


Tony Hillier is an advisor to Opagio with over 30 years of experience in structured finance, valuation, and due diligence across private equity and corporate transactions. Meet the team.